Last reviewed · How we verify
CBP-307
At a glance
| Generic name | CBP-307 |
|---|---|
| Sponsor | Connect Biopharma Australia Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects (PHASE1)
- A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) (PHASE2)
- A Study On Human Mass Balance And Biotransformation (PHASE1)
- Phase 1 Study Accessing the Safety and Tolerability of CBP-307 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBP-307 CI brief — competitive landscape report
- CBP-307 updates RSS · CI watch RSS
- Connect Biopharma Australia Pty Ltd portfolio CI